Sellas Life Sciences' stock surged to a three-year high as its Phase 3 AML trial neared its final readout. The Regal study has recorded 72 events, nearing the 80 required for analysis. Analysts suggest the delay in reaching this threshold could indicate stronger patient survival, driving Wall Street's bullish outlook.